Registered title, quoted from ClinicalTrials.gov
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06194734, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma;
Inclusion criterion 2
Patient with advanced recurrent or metastatic esophageal squamous cell carcinoma previously treated with a PD-1 or PD-L1 inhibitor and at least second-line systemic therapy;
Inclusion criterion 3
Involved in other clinical trials within 4 weeks before enrollment;Prior anti-tumor therapies with radiotherapy, immunotherapy, operation within 4 weeks before enrollment;Prior anti-tumor therapies with small molecule targeting drugs within 2weeks or 5 half-lives (whichever is longer) before enrollment; Prior anti-tumor therapies with chemotherapy within 3 weeks or 5 half-lives (whichever is longer) before enrollment;
Exclusion criterion 7
Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE 5.0 Grade 0 or 1;
Exclusion criterion 8
Eastern Cooperative Oncology Group performance status score of 0 or 1;
Inclusion criterion 5
At least one measurable tumor lesion according to RECIST 1.1;
Inclusion criterion 4
Other kinds of malignancies within 5 years;
Exclusion criterion 2
Known history of human immunodeficiency virus (HIV) infection or current active hepatitis B or C infection;
Exclusion criterion 11
Female patients of childbearing potential with a negative blood pregnancy test completed within 7 days before randomization;
Inclusion criterion 9
Pregnant or lactating women;
Exclusion criterion 12
Female subjects of child-bearing potential and male subjects of reproductive capacity who do not agree to use contraceptive measures during the study and for 6 months after the end of the study.
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06194734, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Males or females aged 18 to 75 years;
- Histologically or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma;
- Patient with advanced recurrent or metastatic esophageal squamous cell carcinoma previously treated with a PD-1 or PD-L1 inhibitor and at least second-line systemic therapy;
- At least one measurable tumor lesion according to RECIST 1.1;
- Eastern Cooperative Oncology Group performance status score of 0 or 1;
- Life expectancy > 12 weeks;
- BMI≥16.0 and weight≥40 kg ;
- Adequate bone marrow, renal, and hepatic function;
- Female patients of childbearing potential with a negative blood pregnancy test completed within 7 days before randomization;
- Patients should participate in the study voluntarily and sign informed consent.
Exclusion Criteria:
- Any patient who is known to have untreated central nervous system (CNS) metastasis;
- Other kinds of malignancies within 5 years;
- Gastrointestinal abnormalities;
- Cardiovascular and cerebrovascular diseases;
- Prior therapies with vascular targeting inhibitor;
- Previously treated with Irinotecan, Docetaxel and Tegafur Gimeracil Oteracil Potassium;
- Involved in other clinical trials within 4 weeks before enrollment;Prior anti-tumor therapies with radiotherapy, immunotherapy, operation within 4 weeks before enrollment;Prior anti-tumor therapies with small molecule targeting drugs within 2weeks or 5 half-lives (whichever is longer) before enrollment; Prior anti-tumor therapies with chemotherapy within 3 weeks or 5 half-lives (whichever is longer) before enrollment;
- Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE 5.0 Grade 0 or 1;
- Uncontrolled massive ascites, pleural or pericardial effusion;
- Severe infection within 4 weeks prior to randomization (CTCAE > Grade 2);
- Known history of human immunodeficiency virus (HIV) infection or current active hepatitis B or C infection;
- Pregnant or lactating women;
- Female subjects of child-bearing potential and male subjects of reproductive capacity who do not agree to use contraceptive measures during the study and for 6 months after the end of the study.
- Other patients are not eligible for enrollment assessed by investigators.
Quoted from ClinicalTrials.gov, NCT06194734, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06194734, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.